A systematic review has mapped how a cellular process called ubiquitination influences type 2 diabetes. Ubiquitination involves enzymes called E3 ligases and deubiquitinating enzymes (DUBs) that modify proteins, affecting their function. The review found that these enzymes form tissue-specific networks that regulate how the body handles insulin and how pancreatic beta cells work.
The research suggests that targeting specific E3 ligases or DUBs could lead to new treatments for type 2 diabetes. However, the evidence is mostly from lab studies, and there is limited human data on which specific targets would be most effective.
No safety information was reported in the review, as it focused on basic biology rather than clinical trials. The main limitation is the lack of human studies confirming these mechanisms.
For now, this research provides a foundation for future drug development but does not change current diabetes care. Patients should continue their prescribed treatments and discuss any questions with their doctor.
